Page 10 - Bio Developments News Today

Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by data and analytics firm GlobalData.

Vertex Pharmaceuticals and CRISPR Therapeutics made history last month by gaining approval for the first CRISPR-based drug, Casgevy.

AstraZeneca and Ionis have received FDA approval for Waiuna, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR).

Irish pharmaceutical company Shorla Oncology and consultancy firm Eversana have announced the U.S. launch of JYLAMVO, the first oral methotrexate solution.

AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) vaccine for infants has received approval for use in China.

Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.

Antibody-drug conjugates (ADC) are booming in the biotech industry this year with mounting investment and M&A deals. Here are five ADC players that have caught the eye of investors in the last 12 months.

Hervé Affagard is the CEO and co-founder of MaaT Pharma and president of Alliance Promotion Microbiote. We sat down with him to discuss the company's promising lead product for gastrointestinal acute graft-versus-host disease.

At Veeva R&D and Quality Summit 2023, Bio Pharma Reporter caught up with Courtney Gilbert, senior director, business system management and innovation, PV operations and global process enablement, at Merck.

A rising demand for biologics means that biotech companies face a multitude of manufacturing challenges, but also plenty of opportunities. We spoke to Kevin Sharp, senior VP and head of sales at Samsung Biologics, to examine what is driving this demand and how the industry, particularly CDMOs, should respond.